Latanoprost - instructions for use, dose, side effects, contraindications

Excipients: sodium chloride - 4,10 mg, sodium dihydrogen phosphate - 4.60 mg, sodium, hydrophosphate - 4.74 mg, benzalkonium chloride - 0.20 mg, purified water - up to 1 ml.

Description:A clear, colorless liquid.

Pharmacotherapeutic group:Antiglaucoma means - prostaglandin F2α analogue synthetic

ATX: & nbsp

S.01.E.E Prostaglandin analogues

S.01.E.E.01 Latanoprost

Pharmacodynamics:

Latanoprost is an analog of prostaglandin F2-alpha and the selective agonist of FP receptors. Reduces intraocular pressure by increasing the outflow of watery moisture, mainly along the uveoscleral pathway.Does not have a significant effect on the production of aqueous humor and does not affect the hemato-ophthalmic barrier.

Reducing the intraocular pressure begins 3-4 hours after drug administration, the maximum effect - after 8-12 hours, the effect lasts for at least 24 hours.

Pharmacokinetics:

Well penetrates through the cornea, while hydrolysis occurs to the biologically active form.

Time to reach the maximum concentration Tc_m_Oh in watery moisture - 2 hours after topical application.

In the eye tissues, latanoprost acid is not practically metabolized; metabolism occurs mainly in the liver. T_1/2 - 17 min. Major metabolites - 1,2-dinor- and 1,2,3,4-tetranor-metabolites have no or weak biological activity. It is excreted by the kidneys.

Indications:Open angle glaucoma, increased intraocular pressure.

Contraindications:

Individual hypersensitivity to latanoprost, benzalkonium chloride or other components of the drug, age to 18 years.

Carefully:

Precautions should be used on patients with aphakia, psevdoafakiey with rupture posterior lens capsule, for patients with known risk factors for macular edema (in treatment of latanoprost described cases of macular edema, includingcystoid); inflammatory, neovascular or congenital glaucoma (due to a lack of experience in the use of the drug).

Pregnancy and lactation:

The use of latanoprost during pregnancy is only possible under the supervision of a doctor and only if the expected benefit for the mother exceeds the risk of developing possible side effects in the fetus.

Latanoprost and its metabolites can be excreted in breast milk. If you need Latanoprost during lactation, breastfeeding should be discontinued.

Dosing and Administration:In the conjunctival sac of the affected eye, instill 1 drop once a day, in the evening; when a dose is missed, the follower is administered normally (i.e., the dose is not doubled).

Side effects:

From the side of the organ of vision: eye irritation (burning sensation, feeling of sand in the eyes, itching, stinging and foreign body sensation), blepharitis, conjunctival hyperemia, eye pain, increased pigmentation of the iris, transient point epithelial erosions, edema of the eyelids, swelling and erosion of the cornea, conjunctivitis, elongation, thickening, increased number and increased pigmentation of the lashes and vellus hair, iritis / uveitis, keratitis, macular edema (includingcystoid), reversal of direction, growth of eyelashes, sometimes causing eye irritation, blurring of vision.

Dermatological reactions: rash; darkening of the eyelid skin and local skin reactions from the eyelids.

From the nervous system: dizziness, headache.

Co the respiratory system: bronchial asthma (including acute seizures or exacerbation of the disease in patients with bronchial asthma in history), dyspnea.

From the musculoskeletal system: pain in the muscles, joint pain.

Other: nonspecific pain in the chest.

Overdose:

Symptoms: irritation of the mucous membrane of the eye, hyperemia of the conjunctiva or episcler.

Treatment: symptomatic.

Interaction:

Pharmaceutically incompatible with eye drops containing thiomersal (precipitation).

When prescribing a combination therapy, eye drops of various drugs should be injected with an interval of at least 5 minutes.

Simultaneous instillation of two analogues of prostaglandins can cause a paradoxical increase in intraocular pressure.

Special instructions:

Causes a gradual change in eye color by increasing the amount of brown pigment in the iris.This effect is mainly seen in patients with mixed iris color, for example, blue-brown, gray-brown, green-brown or yellow-brown, which is explained by an increase in melanin in the stromal melanocytes of the iris. Typically, brown pigmentation spreads concentrically around the pupil to the periphery of the iris of the eyes, while the entire iris or parts of it can acquire a more intense brown color. In the case of an intense change in eye pigmentation, therapy is discontinued.

Patients with uniformly colored eyes of blue, gray, green or brown color change eye color after 2 years of use of the drug are very rare. The developed color change can be irreversible.

Before starting treatment, patients should be informed about the possibility of changing eye color.

Latanoprost can cause gradual changes in eyelashes and fleece hair, such as lengthening, thickening, increasing pigmentation, increasing the density and changing the direction of growth of the eyelashes. The eyelash changes are reversible and pass after the cessation of treatment.

Patients who apply drops to only one eye may develop heterochromia.

The preparation contains benzalkonium chloride, which can be absorbed by contact lenses. Before instilling eye drops, contact lenses should be removed; You can insert the lenses only 15 minutes after instillation.

Effect on the ability to drive transp. cf. and fur:

Patients who, after the application of eye drops, have a transient fogging of vision, it is not recommended to drive vehicles or work with mechanisms before it is restored.

Form release / dosage:Eye drops 0.005%.

Packaging:

2.5 ml in the bottles-dropper.

1 bottle-dropper along with the instructions for use are placed in a pack of cardboard.

Storage conditions:

Store in a dark place at a temperature of 2 to 8 ° C. Do not freeze. The opened vial should be stored at a temperature of no higher than 25 ° C for 4 weeks.

Keep out of the reach of children.

Shelf life:

2 years.

Do not use after the specified time on the package.

Terms of leave from pharmacies:On prescription

Registration number:LP-000190

Date of registration:26.01.2011 / 04.05.2016

Expiration Date:Unlimited

The owner of the registration certificate:Kern Pharma S.L.Kern Pharma S.L. Spain

Manufacturer: & nbsp

MONTEFARMACO, S.p.A. Italy

Representation: & nbspINDUKERN-RUS LLCINDUKERN-RUS LLCRussia

Information update date: & nbsp12.03.2018

Illustrated instructions

Instructions

Latanoprost (Latanoprost)